Inozyme's Douglas Treco moves downstairs to replace retiring Axel Bolte
US biopharma Inozyme Pharma (Nasdaq: INZY) has announced that founding chief executive officer Axel Bolte will retire from his current role, to be replaced by Douglas Treco.
Currently, Dr Treco is the chairman of the Inozyme’s board of directors, so he will make the unusual move from the boardroom into the top operational role.
"I believe INZ-701 is a unique product candidate which has the potential to transform the treatment of multiple severe disorders"Prior to serving on Inozyme’s board, Dr Treco was co-founder, president, and chief executive of Ra Pharmaceuticals, a company acquired in 2020 by UCB (Euronext: UCB) for $2.5 billion. In that role, he oversaw the discovery and development of zilucoplan in myasthenia gravis, which is currently under review for marketing approval in the USA and European Union.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze